Full Press Release Details
Publication Date: August 6, 2024 Published By: Breaking Cancer News Article Link: https://breakingcancernews.com/2024/08/06/a-new-company-and-new-approach-to-brain-cancer/
We are finally seeing some genuine progress in treating brain cancer, with new treatments and trials going on nationwide and worldwide.
This week, I write about one company that’s moving the needle, NeOnc Technologies.
NeOnc Technologies has begun a Phase 2 clinical study that seeks further safety and preliminary evidence of biological effects of its lead drug candidate, NEO100, on certain cancers of the brain and central nervous system.
The trial highlights the ability of the NEO™ technology platform to produce novel drugs and delivery methods designed to overcome the persistent challenges in delivering chemotherapeutics through the blood-brain barrier.
This is a major development, as there are very few treatments for brain cancer.
Also in this issue, writer Preetam Kaushik points out that more than 70% of all cancer-related deaths in 2020 occurred in low- and middle-income countries. Many of these deaths could have been prevented through vaccinations, screening protocols, and prompt access to oncological infrastructure.
The situation is particularly acute in India, which recently dethroned China as the most populous country on the planet. There were around 1.46 million new cancer cases in India in 2022, with a projected annual increase of 12.8% until 2025.
According to the Ministry of Health and Family Welfare, there is an 80% shortfall in specialist doctors in rural healthcare centers.
Sandeep Kumar, founder and CEO of the DigiSwasthya Foundation , is working hard to change things globally. He is determined to improve access to affordable medical care in rural India. It is a journey worth reading.
Meanwhile, writer Sharyn Rosenbaum points out that most women are told to start regular mammograms at age 40, with the goal of catching breast cancer early and saving lives. Yet despite advances in mammography technology and medical treatments, breast cancer remains the second leading cause of cancer death for women in the U.S. and the most common cancer in women except for skin cancer .
Breast cancer is also the most common cancer among adolescents and young adults (ages 15-39), accounting for 30% of cancers in this age group. This rate has been rising for nearly the past two decades.
With more women under 40 getting breast cancer – many of whom are diagnosed at a late stage – does the age-based approach to screening still make sense?
The WISDOM study seeks to answer this question by testing a personalized approach to screening for women as young as 30, compared to standard-of-care annual mammograms beginning at age 40.